Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.

Lange JM, Perriens J, Kuritzkes D, Zewdie D.

AIDS. 2004 Jun;18 Suppl 3:S69-74. Review.

PMID:
15322488
2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
3.
4.
5.

The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?

Giordano TP, Suarez-Almazor ME, Grimes RM.

Curr HIV/AIDS Rep. 2005 Nov;2(4):177-83. Review.

PMID:
16343375
6.

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.

Lucas GM.

J Antimicrob Chemother. 2005 Apr;55(4):413-6. Epub 2005 Feb 18. Review.

PMID:
15722389
7.

A review of barriers and facilitators of HIV treatment among injection drug users.

Wood E, Kerr T, Tyndall MW, Montaner JS.

AIDS. 2008 Jul 11;22(11):1247-56. doi: 10.1097/QAD.0b013e3282fbd1ed. Review.

PMID:
18580603
8.

[AIDS treatment in Africa: the risk of antiretroviral resistance].

Hamers RL, Schuurman R, van Vugt M, Derdelinckx I, Rinke de Wit TF.

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2666-71. Review. Dutch.

PMID:
18179083
9.

AIDS in the Third World: how to stop the HIV infection?

De Clercq E.

Verh K Acad Geneeskd Belg. 2007;69(2):65-80. Review.

PMID:
17550059
10.

Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries.

Kaufmann GR, Smith D, Bucher HC, Phanuphak P, Sendi PP, Mbidde EK, Cooper DA, Battegay M.

Expert Opin Investig Drugs. 2002 Sep;11(9):1303-13. Review.

PMID:
12225251
11.

Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment.

Nguyen VK, Ako CY, Niamba P, Sylla A, Tiendrébéogo I.

AIDS. 2007 Oct;21 Suppl 5:S31-5. doi: 10.1097/01.aids.0000298100.48990.58. Review.

PMID:
18090265
12.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
13.
14.

Antiretroviral drug development: the challenge of cost and access.

Dunne M.

AIDS. 2007 Jul;21 Suppl 4:S73-9. Review.

PMID:
17620756
15.

Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Kerr T, Walsh J, Lloyd-Smith E, Wood E.

Curr HIV/AIDS Rep. 2005 Nov;2(4):200-5. Review.

PMID:
16343379
16.
17.

Lessons learned from use of highly active antiretroviral therapy in Africa.

Akileswaran C, Lurie MN, Flanigan TP, Mayer KH.

Clin Infect Dis. 2005 Aug 1;41(3):376-85. Epub 2005 Jun 30. Review.

PMID:
16007536
18.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
19.

Current and future antiretroviral treatment options in paediatric HIV infection.

Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R.

Clin Drug Investig. 2008;28(6):375-97. Review.

PMID:
18479179
20.

Supplemental Content

Support Center